MAIA Biotechnology Files Routine 8-K, No New Material Info
Ticker: MAIA · Form: 8-K · Filed: Jan 30, 2024 · CIK: 1878313
| Field | Detail |
|---|---|
| Company | Maia Biotechnology, INC. (MAIA) |
| Form Type | 8-K |
| Filed Date | Jan 30, 2024 |
| Risk Level | low |
| Pages | 3 |
| Reading Time | 3 min |
| Sentiment | neutral |
Complexity: simple
Sentiment: neutral
Topics: compliance, routine-filing
TL;DR
**MAIA filed a routine 8-K; nothing new to see here.**
AI Summary
MAIA Biotechnology, Inc. filed an 8-K on January 30, 2024, reporting an event that occurred on January 24, 2024. This filing is a standard current report and does not disclose specific financial transactions, new agreements, or significant operational changes. For investors, this means there's no immediate new information impacting the company's valuation or strategic direction, and it primarily serves as a routine compliance update.
Why It Matters
This filing is a standard compliance update, indicating no new material events have occurred that would immediately affect MAIA Biotechnology's stock price or future prospects.
Risk Assessment
Risk Level: low — The filing is a standard procedural update and does not contain information that introduces new risks or changes existing ones.
Analyst Insight
A smart investor would note this as a routine filing and look for more specific 8-K filings (e.g., Item 1.01, 2.01, 5.02) for material news that could impact MAIA Biotechnology's stock.
Key Players & Entities
- MAIA Biotechnology, Inc. (company) — the registrant filing the 8-K
- January 24, 2024 (date) — date of the earliest event reported
- January 30, 2024 (date) — date the 8-K was filed
- 001-41455 (other) — Commission File Number for MAIA Biotechnology, Inc.
- NYSE American (other) — exchange where MAIA Common Stock is registered
FAQ
What is the purpose of this 8-K filing by MAIA Biotechnology, Inc.?
This 8-K filing is a Current Report pursuant to Section 13 or 15(d) of The Securities Exchange Act of 1934, indicating a routine disclosure of an event that occurred on January 24, 2024. It does not specify a particular material event beyond being a general 'Other Events' and 'Financial Statements and Exhibits' filing.
When was the earliest event reported in this 8-K filing?
The earliest event reported in this 8-K filing occurred on January 24, 2024, as stated in the 'Date of Report (Date of earliest event reported)' section.
What is MAIA Biotechnology, Inc.'s trading symbol and on which exchange is its common stock registered?
MAIA Biotechnology, Inc.'s trading symbol is 'MAIA', and its Common Stock is registered on the NYSE American exchange, as indicated under 'Securities registered pursuant to Section 12(b) of the Act'.
Is MAIA Biotechnology, Inc. considered an emerging growth company?
Yes, MAIA Biotechnology, Inc. has indicated by check mark that it is an 'emerging growth company' as defined in Rule 405 of the Securities Act of 1933 or Rule 12b-2 of the Securities Exchange Act of 1934.
What is the business address of MAIA Biotechnology, Inc.?
The business address of MAIA Biotechnology, Inc. is 444 West Lake Street, Suite 1700, Chicago, IL 60606, with a telephone number of (312) 416-8592.
Filing Stats: 836 words · 3 min read · ~3 pages · Grade level 15.1 · Accepted 2024-01-30 09:00:30
Filing Documents
- d741606d8k.htm (8-K) — 26KB
- d741606dex991.htm (EX-99.1) — 10KB
- 0001193125-24-018845.txt ( ) — 165KB
- maia-20240124.xsd (EX-101.SCH) — 3KB
- maia-20240124_lab.xml (EX-101.LAB) — 18KB
- maia-20240124_pre.xml (EX-101.PRE) — 11KB
- d741606d8k_htm.xml (XML) — 4KB
Forward-looking Statements
Forward-looking Statements The Company cautions that all statements, other than statements of historical facts, contained in this Current Report on Form 8-K, or furnished herewith, are forward-looking statements. Forward-looking statements are subject to known and unknown risks, uncertainties, and other factors that may cause our or our industry's actual results, levels or activity, performance or achievements to be materially different from those anticipated by such statements. The use of words such as "may," "might," "will," "should," "could," "expect," "plan," "anticipate," "believe," "estimate," "project," "intend," "future," "potential," or "continue," and other similar expressions are intended to identify forward looking statements. However, the absence of these words does not mean that statements are not forward-looking. All forward-looking statements are based on current estimates, assumptions and expectations by our management that, although we believe to be reasonable, are inherently uncertain. Any forward-looking statement expressing an expectation or belief as to future events is expressed in good faith and believed to be reasonable at the time such forward-looking statement is made. However, these statements are not guarantees of future events and are subject to risks and uncertainties and other factors beyond our control that may cause actual results to differ materially from those expressed in any forward-looking statement, including, but not limited to: (i) the initiation, timing, cost, progress and results of our preclinical and clinical studies and our research and development programs, (ii) our ability to advance product candidates into, and successfully complete, clinical studies, (iii) the timing or likelihood of regulatory filings and approvals, (iv) our ability to develop, manufacture and commercialize our product candidates and to improve the manufacturing process, (v) the rate and degree of market acceptance of our product candidates, (vi)
Financial Statements and Exhibits
Financial Statements and Exhibits. (d) Exhibits: Exhibit No. Description 99.1 Press release, dated January 24, 2024 104 Cover Page Interactive Data File (embedded within the Inline XBRL Document)
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. Dated: January 30, 2024 MAIA BIOTECHNOLOGY, INC. By: /s/ Vlad Vitoc Name: Vlad Vitoc Title: Chief Executive Officer